Revolution Medicines (RVMD) Insider B. Sells $68K of Stock
Revolution Medicines Chief Development Officer Alan B. Sandler sold 341 shares on September 16, 2026, via a pre-arranged plan.
Reviewed by automated data checks against the source filing. How we make and check alerts
Sandler Alan B., Chief Development Officer at Revolution Medicines, Inc. ($RVMD), sold 341 shares at an average price of $199.24, worth about $67,940.67, on September 16, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $RVMD is down 2.6% after 1 week, down 9.2% after 1 month and down 9.2% to date (from the $195.92 close on Sep 16, 2026).
RVMD
Revolution Medicines, Inc.
Key Points
- Chief Development Officer Alan B. Sandler sold 341 shares of Revolution Medicines, Inc. ticker RVMD on September 16, 2026, at a price of $199.24 per share.
- The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, totaling about $67,940.
- Revolution Medicines trades on the NasdaqGS and prepares to share its next quarterly financial update on November 4, 2026.
Get $RVMD trade alerts by text
We text you when insiders, Congress or big funds trade $RVMD. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Revolution Medicines, Inc. alert may contain errors. Disclosures
Revolution Medicines, Inc. Chief Development Officer Alan B. Sandler sold 341 shares of the company on September 16, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the shares were sold at a price of $199.24 for a total value of about $67,940.67. The planned transaction was executed under a pre-arranged Rule 10b5-1 trading plan. On the day of the sale, Revolution Medicines shares closed at $195.92.
Inside Sandler's RVMD Trade
The Chief Development Officer's sale involved a modest block of 341 shares at $199.24 apiece. Insider sales carried out under pre-scheduled trading plans are common for executives seeking to manage personal portfolios without running afoul of insider trading rules.
Other Institutional Activity in Revolution Medicines
Other large funds made substantial moves in RVMD earlier in the year. Farallon Capital Management LLC trimmed its holdings by 54,421 shares, ending with 13,550,796 shares worth about $2,411,499,747. Baker Bros. Advisors, LP grew its holdings by 1,888,116 shares, ending with 11,443,357 shares valued near $2,036,459,888. Jupiter Topco LLC increased its holdings by 5,368,072 shares, ending with 10,736,145 shares worth roughly $1,910,604,436. Darwin Global Management, Ltd. added 8,418,823 shares to hold 10,629,822 shares valued at approximately $1,891,683,194. Nextech Invest, Ltd. kept its stake steady at 7,601,087 shares worth about $1,352,689,493.
Revolution Medicines, Inc. Stock Down 3.8%
The company recently traded around $182.01, sitting below its 50-day moving average of $203.12 and above its 200-day moving average of $151.62. The stock has traded between a 52-week low of $52.48 and a high of $224.31.
Recent Earnings
The firm reported a trailing twelve-month earnings per share of negative $8.87. Wall Street maintains a strong buy consensus with a mean price target of $257.80.
Insider Buying and Selling at Revolution Medicines, Inc.
Prior insider transactions included purchases by Sushil Patel and Flavia Borellini on June 18, 2026, alongside Chief Financial Officer Jack Anders selling 20,000 shares on June 24, 2026.
Analysts Set New Price Targets
Morgan Stanley initiated coverage on September 10, 2026, with an Overweight rating and a $255.00 price target. Additional research updates followed from firms including B of A Securities and Brookline Capital.
About Revolution Medicines
Revolution Medicines is a Redwood City, California-based biotechnology firm developing targeted oncology therapies for patients with RAS-addicted cancers.
Bottom Line
Investors will look toward the company's next earnings report on November 4, 2026, for further updates on its clinical pipeline.
Related Filing Alerts
Source: Sandler Alan B.'s Form 4 filing on $RVMD (Sep 16, 2026). Find the original filing: RVMD Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts